Zonisamide for the treatment of myoclonic seizures in progressive myoclonic epilepsy: an open‐label study
- 1 March 2008
- journal article
- clinical trial
- Published by Wiley in Epileptic Disorders
- Vol. 10 (1) , 31-34
Abstract
Purpose: To examine the safety and efficacy of zonisamide in treating myoclonic seizures associated with progressive myoclonic epilepsy (PME), in an open‐label setting. Methods: Thirty patients with refractory PME (aged ≥ 5 years), who were taking up to three antiepileptic drugs, received adjunctive zonisamide (≤ 6 mg/kg/day) therapy for 16 weeks. Myoclonic seizures were recorded daily over a 24‐hour period or in 10‐minute epochs in the morning, afternoon, and evening. Safety was assessed via adverse events (AEs); efficacy was measured by the percentage of patients experiencing a ≥ 50% decrease in myoclonic seizure frequency from baseline. Results: Treatment‐related AEs, experienced by 53% (n = 16/30) of patients, led to five patients discontinuing zonisamide. The most common AEs were decreased appetite, somnolence, and asthenia. Overall, 36% of patients (n = 10/28) had a ≥ 50% reduction in myoclonic seizure frequency. Conclusions: These results suggest that zonisamide may be useful in the treatment of patients with PME. However, due to the size and open‐label character of this study, further research is required.Keywords
This publication has 7 references indexed in Scilit:
- Report of the ILAE Classification Core GroupEpilepsia, 2006
- Antimyoclonic effect of levetiracetam in MERRF syndromeJournal of the Neurological Sciences, 2006
- Classification of the Myoclonic EpilepsiesEpilepsia, 2003
- Efficacy of levetiracetam in a patient with Unverricht-Lundborg progressive myoclonic epilepsyNeurology, 2003
- Progressive Myoclonic EpilepsiesJournal of Child Neurology, 2002
- Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patientsEpilepsy Research, 1998
- Progressive myoclonus epilepsy treated with zonisamideNeurology, 1988